Latest Cash Runway News

Radiopharm Theranostics reported a A$56.3 million comprehensive loss for fiscal 2026, with operating cash outflows rising to A$52.8 million and cash falling to A$4.1 million. The company says further funding is required, while auditors flag a material uncertainty over its ability to continue as a going concern.

Antares Metals delivered its busiest exploration year yet, reporting high-grade copper, uranium and gold results across Queensland and Western Australia. But the explorer ended FY2026 with just $581,438 in cash, while its auditor flagged a material uncertainty over its ability to continue as a going concern.

Rimfire Pacific Mining has expanded its NSW scandium inventory and reported preliminary leach results that could support a simpler extraction route. But the ASX explorer ended FY2026 with $583,770 in cash, negative working capital and an auditor-highlighted material uncertainty over its ability to continue as a going concern.

Celsius Resources has reported a sharply wider FY2026 loss after impairing its disputed interest in the MCB copper-gold project, while an Equinaire credit bid has complicated ownership of the Philippine asset. The company is relying on a pending Opuwo sale, fresh financing and arbitration to keep its development strategy alive.

Maverick Minerals finished FY2026 with $5.3 million in cash after raising $6 million, but warned that further funding will be needed to sustain its expanded exploration program. The auditor highlighted a material uncertainty over the company’s ability to continue as a going concern.

Clara Resources has pivoted decisively from coal to gold, but its Mareeba ambition sits alongside a $7.36 million annual loss, only $112,000 in year-end cash and a disclosed material uncertainty over going concern. The company is now relying on drilling, asset-sale proceeds and further capital to keep the strategy moving.

Sabre Resources has expanded into a 4,000-square-kilometre Northern Territory gold and copper-gold portfolio, but its FY2026 loss more than doubled as cash declined. The company now has drilling underway and fresh capital, alongside a growing funding and dilution burden.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

Norwest Minerals has strengthened the technical case for its Bulgera heap-leach project with a revised 191,000-ounce resource and 86% bottle-roll recoveries. But the ASX-listed explorer ended FY2026 with $394,541 in cash, and its auditor highlighted material uncertainty over its ability to continue as a going concern.

DevEx Resources has emerged from FY2026 with a 9,200 square kilometre uranium landholding in the Northern Territory, $27.2 million in cash and a multi-target drilling campaign underway. Early alteration at KP and shallow mineralisation at Big Radon provide technical encouragement, but the exploration case remains dependent on follow-up drilling and assays.

Resource Base Limited (ASX:RBX) reduced its FY2026 loss, but ended the year with only $140,776 in cash and an auditor warning of material uncertainty over its ability to continue as a going concern. The company is relying on fresh capital to advance early-stage titanium targets in South Australia.

Rhythm Biosciences has moved ColoSTAT and geneType into commercial use, recording its first sales during FY2026. But with sales revenue of just $85,339, a $5.93 million loss and an auditor-flagged going-concern uncertainty, the next phase will be judged on cash generation and repeat adoption.